For: | Geraghty NJ, Watson D, Adhikary SR, Sluyter R. P2X7 receptor in skin biology and diseases. World J Dermatol 2016; 5(2): 72-83 [DOI: 10.5314/wjd.v5.i2.72] |
---|---|
URL: | https://www.wjgnet.com/2218-6190/full/v5/i2/72.htm |
Number | Citing Articles |
1 |
Ronald Sluyter. Protein Reviews. Advances in Experimental Medicine and Biology 2017; 1051: 17 doi: 10.1007/5584_2017_59
|
2 |
Geoffrey Burnstock. Purinergic Signalling: Therapeutic Developments. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00661
|
3 |
P.A.F. Pacheco, R.M.S. Galvão, A.F.M. Faria, N.l. Von Ranke, M.S. Rangel, T.M. Ribeiro, M.l. Bello, C.R. Rodrigues, V.F. Ferreira, D.R. da Rocha, R.X. Faria. 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine Macrophages. Bioorganic & Medicinal Chemistry 2019; 27(8): 1449 doi: 10.1016/j.bmc.2018.11.036
|
4 |
Jessica Gaff, Fitri Octaviana, Connie Jackaman, Peter Kamerman, John Papadimitriou, Silvia Lee, Jenjira Mountford, Patricia Price. Expression in skin biopsies supports genetic evidence linking CAMKK2, P2X7R and P2X4R with HIV-associated sensory neuropathy. Journal of NeuroVirology 2023; 29(3): 241 doi: 10.1007/s13365-023-01134-2
|
5 |
Geoffrey Burnstock, Gillian E. Knight. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signalling 2018; 14(1): 1 doi: 10.1007/s11302-017-9593-0
|
6 |
Mathias Hohl, Felix Götzinger, Simone Jäger, Lea Wagmann, Mert Tokcan, Thomas Tschernig, Jörg Reichrath, Jan M. Federspiel, Peter Boor, Markus R. Meyer, Felix Mahfoud, Michael Böhm. Assessing phototoxic drug properties of hydrochlorothiazide using human skin biopsies. Communications Biology 2025; 8(1) doi: 10.1038/s42003-025-08064-1
|
7 |
N J Geraghty, L Belfiore, D Ly, S R Adhikary, S J Fuller, W Varikatt, M L Sanderson-Smith, V Sluyter, S I Alexander, R Sluyter, D Watson. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease. Clinical and Experimental Immunology 2017; 190(1): 79 doi: 10.1111/cei.13005
|
8 |
T.B.-D. McEwan, R.A. Sophocleous, P. Cuthbertson, K.J. Mansfield, M.L. Sanderson-Smith, R. Sluyter. Autocrine regulation of wound healing by ATP release and P2Y2 receptor activation. Life Sciences 2021; 283: 119850 doi: 10.1016/j.lfs.2021.119850
|
9 |
Nicholas J. Geraghty, Kylie J. Mansfield, Stephen J. Fuller, Debbie Watson, Ronald Sluyter. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice. Purinergic Signalling 2017; 13(4): 405 doi: 10.1007/s11302-017-9569-0
|
10 |
Aziz Ghaderpour, Ju‐Young Jeong, Youn‐Hee Kim, Yunyun Zou, Kyung‐Sun Park, Eun‐Ji Hong, Young‐Jae Koh, Seung‐Yong Seong. Taurodeoxycholate, a GPCR19 agonist, ameliorates atopic dermatitis in Balb/c mice. European Journal of Immunology 2023; 53(5) doi: 10.1002/eji.202250048
|
11 |
Ronald Sluyter, Kara L. Vine. N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1βRelease from Murine Macrophages. Mediators of Inflammation 2016; 2016: 1 doi: 10.1155/2016/2097219
|
12 |
Geoffrey Burnstock. The therapeutic potential of purinergic signalling. Biochemical Pharmacology 2018; 151: 157 doi: 10.1016/j.bcp.2017.07.016
|
13 |
Ronald Sluyter, Sahil Adriouch, Stephen J. Fuller, Annette Nicke, Reece A. Sophocleous, Debbie Watson. Animal Models for the Investigation of P2X7 Receptors. International Journal of Molecular Sciences 2023; 24(9): 8225 doi: 10.3390/ijms24098225
|